Comparative Pharmacology
Head-to-head clinical analysis: DUVOID versus VUITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUVOID versus VUITY.
DUVOID vs VUITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-1A adrenergic receptor antagonist; relaxes smooth muscle in the bladder neck and prostate, reducing outflow resistance.
VUITY (pilocarpine hydrochloride ophthalmic solution) 1.25% is a muscarinic receptor agonist. It induces miosis by contracting the iris sphincter muscle, increasing the eye's depth of focus and improving near visual acuity. It acts via the ciliary muscle to reduce the diameter of the pupil, creating a pinhole effect that enhances depth of focus.
100 mg orally three times daily.
One drop of VUITY (pilocarpine 1.25% ophthalmic solution) instilled into each eye three times daily at approximately 6-8 hour intervals.
None Documented
None Documented
Terminal elimination half-life is 12–15 hours in patients with normal renal function; prolonged to 24 hours or more in moderate-to-severe renal impairment.
Terminal half-life: 134 hours (range 110-170 hours). Clinical context: allows once-weekly dosing; steady-state achieved after 2-3 months.
Renal elimination accounts for approximately 90% of a dose as unchanged drug; biliary/fecal excretion is minor (<10%).
Primarily via hepatic metabolism; inactive metabolites excreted in urine (approximately 90%) and feces (approximately 10%).
Category C
Category C
Cholinergic Agonist
Cholinergic Agonist